Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy agree Actos generic deal

Ranbaxy Laboratories has reached an agreement with Takeda to launch a generic version of its blockbuster diabetes drug, Actos, in the US

Ranbaxy Laboratories has reached an agreement with Takeda Pharmaceuticals to launch a generic version of its blockbuster diabetes drug treatment, Actos (pioglitazone hydrochloride), in the US.

The deal will see the two companies resolve patent litigation that has been outstanding since makers of Actos, Takeda sued Ranbaxy, along with Watson Pharmaceuticals and Mylan Laboratories, in 2003 over potential generic versions.

Full terms of the settlement have yet to be disclosed, though Takeda will grant Ranbaxy, India's largest pharmaceutical company, a non-exclusive royalty free license to its US patents covering Actos. Ranbaxy will be allowed to launch its generic version in the US on August 17, 2012, or earlier under certain circumstances.

Takeda had previously announced a similar agreement with Watson Pharmaceuticals regarding their own generic version of Actos.

Jim Meehan, vice president of sales and distribution for Ranbaxy Pharmaceuticals Inc (RPI), part of the Ranbaxy family, said: "This agreement will allow RPI to bring to patients with diabetes a generic alternative in this important therapeutic area."

Actos is one of Takeda's biggest selling drugs, achieving around $3.4bn in brand sales for 2009.

16th March 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...

Infographics